- Home
- NRO vs VIGL Comparison
NRO vs VIGL Comparison
Compare NRO & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- VIGL
- Stock Information
- Founded
- NRO 2003
- VIGL 2020
- Country
- NRO United States
- VIGL United States
- Employees
- NRO N/A
- VIGL N/A
- Industry
- NRO Finance/Investors Services
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- VIGL Health Care
- Exchange
- NRO Nasdaq
- VIGL Nasdaq
- Market Cap
- NRO 189.8M
- VIGL 148.7M
- IPO Year
- NRO N/A
- VIGL 2022
- Fundamental
- Price
- NRO $4.07
- VIGL $3.47
- Analyst Decision
- NRO
- VIGL Buy
- Analyst Count
- NRO 0
- VIGL 5
- Target Price
- NRO N/A
- VIGL $16.60
- AVG Volume (30 Days)
- NRO 239.4K
- VIGL 79.9K
- Earning Date
- NRO 01-01-0001
- VIGL 11-05-2024
- Dividend Yield
- NRO 11.41%
- VIGL N/A
- EPS Growth
- NRO N/A
- VIGL N/A
- EPS
- NRO N/A
- VIGL N/A
- Revenue
- NRO N/A
- VIGL N/A
- Revenue This Year
- NRO N/A
- VIGL N/A
- Revenue Next Year
- NRO N/A
- VIGL N/A
- P/E Ratio
- NRO N/A
- VIGL N/A
- Revenue Growth
- NRO N/A
- VIGL N/A
- 52 Week Low
- NRO $2.51
- VIGL $2.47
- 52 Week High
- NRO $3.45
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- NRO 72.39
- VIGL 46.12
- Support Level
- NRO $3.80
- VIGL $3.66
- Resistance Level
- NRO $4.14
- VIGL $3.83
- Average True Range (ATR)
- NRO 0.07
- VIGL 0.28
- MACD
- NRO -0.00
- VIGL 0.01
- Stochastic Oscillator
- NRO 77.42
- VIGL 32.53
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.